Androgen Receptor in Cancers: Not Only Prostate

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 1717

Special Issue Editor


E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 Naples, Italy
Interests: castration-resistant prostate cancer (CRPC); extracellular vesicles; sex steroid hormones in cancers (breast, prostate, pancreatic and colon); triple negative breast cancer; sex steroid receptors; growth factor receptors signaling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The androgen receptor belongs to the sex steroid receptor family and is commonly known as a transcription factor that is directly involved in prostate cancer (PC) progression. Recent advances have not only discovered that AR influences PC behavior by controlling the rapid activation of different signaling transduction pathways, but also that this steroid receptor affects the pathogenesis and advancement of cancer in a plethora of other organs in addition to the prostate.  The role of AR in breast cancer is now better known, especially in the most aggressive subtype triple negative breast cancer (TNBC); furthermore, it is also clear that AR can act upon the development and progression of non-hormone related cancers such as gastroesophageal and lung cancers or melanoma. These tumors are known as gender-related cancers because their incidence and mortality are unequal between men and women, displaying the highest number in the former.  The study and understanding of mechanisms influencing the differences between the two sexes could be useful to develop preventive screening or therapeutic strategies to limit the onset of these tumors.

This Special Issue aims to increase the knowledge about the role of the androgen receptor in all cancers that are not usually dependent on androgens in the same way as for prostate cancer. All original articles and reviews describing AR action in cancers except prostate are welcome.

Research areas may include (but are not limited to) the following:

  • AR in cancer;
  • AR in the cancer microenvironment;
  • AR in exosomes;
  • AR in cancer therapy.

I look forward to receiving your contributions.

Dr. Pia Giovannelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • androgens
  • androgen receptor
  • gender
  • gender-related cancers
  • lung cancer
  • melanoma
  • gastrointestinal cancers
  • bladder cancer
  • brain cancers
  • sarcomas

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 793 KiB  
Article
Testicular Cancer Incidence among Obstructive Sleep Apnea (OSA) Patients: South Korean National Health Insurance Data
by Marn Joon Park, Kyung-Do Han, Jae Hoon Cho and Ji Ho Choi
Cancers 2023, 15(13), 3273; https://doi.org/10.3390/cancers15133273 - 21 Jun 2023
Cited by 1 | Viewed by 1428
Abstract
Obstructive sleep apnea (OSA) has been linked to an increased risk of acquiring many types of cancer. No data on the prevalence of testicular cancer in OSA patients have been reported in the literature. The goal of the present investigation is to find [...] Read more.
Obstructive sleep apnea (OSA) has been linked to an increased risk of acquiring many types of cancer. No data on the prevalence of testicular cancer in OSA patients have been reported in the literature. The goal of the present investigation is to find out the impact of OSA on the incidence of testicular cancer based on the Korea National Health Insurance Service (KNHIS) dataset. A cohort of adult male patients newly registered with OSA in the KNHIS data from 2007 to 2014 who had no history of any previous cancer diagnosis was included. The main outcome measure was newly diagnosed testicular cancer in the National Medical Expenses Support Program. The control group was set at five times larger than the OSA group, and it was matched with age and sex. The cumulative incidence and hazard ratio (HR) for the development of testicular cancer were compared between the OSA and control groups. Further subgroup analysis was conducted in the three different age groups. In the study period, a total of 152,801 male adult patients newly diagnosed with OSA were included, whereas 764,005 individuals were recruited as the control group. The HR of OSA for developing testicular cancer was 1.58 (95% confidence interval [CI]: 0.92–2.60), showing no significant HR regardless of confounding adjustment. However, the subgroup analysis revealed a significantly increased HR to develop testicular cancer of 3.39 (95% CI: 1.08–10.06) in groups aged more than 65, whereas the age ranges of 20–40 and 40–64 showed no significance (1.19 (0.44–2.75) and 1.27 (0.50–2.80), respectively). OSA may not influence the incidence of testicular cancer in the general adult population. However, compared to younger males, males over 65 may be more susceptible to OSA when it comes to developing testicular cancer. Full article
(This article belongs to the Special Issue Androgen Receptor in Cancers: Not Only Prostate)
Show Figures

Figure 1

Back to TopTop